MBA MBA - Egetis Therapeutics Chief Officer
| EGTX Stock | SEK 5.62 0.01 0.18% |
Insider
MBA MBA is Chief Officer of Egetis Therapeutics AB
| Age | 63 |
| Phone | 46 86 79 72 10 |
| Web | https://www.egetis.com |
Egetis Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.136) % which means that it has lost $0.136 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2602) %, meaning that it generated substantial loss on money invested by shareholders. Egetis Therapeutics' management efficiency ratios could be used to measure how well Egetis Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Claes Drougge | IAR Systems Group | 63 | |
| Dan Mogren | Clinical Laserthermia Systems | N/A | |
| Jonas Tidqvist | KABE Group AB | 54 | |
| Anders Ersson | Sedana Medical AB | 54 | |
| Johan Skogeryd | KABE Group AB | N/A | |
| Olle Svensk | Embellence Group AB | 55 | |
| Robert Smolander | Embellence Group AB | N/A | |
| Rolf Bornschein | Clinical Laserthermia Systems | N/A | |
| Marie MSc | Clinical Laserthermia Systems | 44 | |
| Bertolt Gartner | Norva24 Group AB | 56 | |
| Jeff Borcherding | Immunovia publ AB | N/A | |
| Robert Hrd | Mekonomen AB | 57 | |
| Arta Mandegari | eEducation Albert AB | 37 | |
| Mikael Blomqvist | KABE Group AB | 42 | |
| Alf Ekstrm | KABE Group AB | 67 | |
| Marie Karlsson | Embellence Group AB | N/A | |
| Peter MD | Sedana Medical AB | 52 | |
| Stephan MSc | Clinical Laserthermia Systems | 68 | |
| Christian Tomadini | Embellence Group AB | N/A | |
| Jesper Rydaker | IAR Systems Group | 53 | |
| Anders Vallenljord | IAR Systems Group | 55 | |
Management Performance
| Return On Equity | -0.26 | |||
| Return On Asset | -0.14 |
Egetis Therapeutics Leadership Team
Elected by the shareholders, the Egetis Therapeutics' board of directors comprises two types of representatives: Egetis Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Egetis. The board's role is to monitor Egetis Therapeutics' management team and ensure that shareholders' interests are well served. Egetis Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Egetis Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Torsten Almn, Founder | ||
| Louis Ignarro, Founder | ||
| Rob Towart, Founder | ||
| Associate Brurok, Founder | ||
| Yilmaz Mahshid, Chief Officer | ||
| Ingemar Lundstrm, Founder | ||
| MBA MBA, Chief Officer | ||
| Peter Verwaijen, Global Strategy | ||
| Nicklas Westerholm, Chief Officer | ||
| Karl Hard, Head VP |
Egetis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Egetis Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (7.54) % | |||
| Current Valuation | 698.73 M | |||
| Shares Outstanding | 249.59 M | |||
| Shares Owned By Insiders | 52.07 % | |||
| Shares Owned By Institutions | 14.16 % | |||
| Price To Book | 1.52 X | |||
| Price To Sales | 42.39 X | |||
| Revenue | 38.24 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.